



# Phospholipase A<sub>2</sub>, Lipid Signaling and Lipidomics in Innate Immunity and Inflammation

The Eicosanoid Research Division\*

Jesús Balsinde

*Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC),  
47003 Valladolid, Spain, and  
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM),  
28029 Madrid, Spain*

\*<http://www.balsinde.org>

December 1, 2020

**There is some discrepancy as to what really is the kick-off date of the Eicosanoid Research Division (or the Eicosanoid Laboratory, as it came to be known first). Truth be told, the thing took its first *official* steps in September 2000, with my definite arrival in Valladolid. Beginnings are always difficult, and mine in the capital of the Old Castile was no exception. Because of this and a few other things, the details of which I will spare the reader, I normally set the beginning of our scientific adventures in Castile just one year after, in the fall of 2001, which is when something resembling a biomedical research lab was finally available and a few people were around to start the journey along. Our subject matter, obviously, lipids and all things lipids. Why always lipids?, you may ask. Good question. For the moment being, let's say that lipids play fundamental roles in the regulation of cell signaling, and that imbalances in lipids and lipid-mediated signaling cause a large number of diseases, including type 2 diabetes, Alzheimer, arthritis and atherosclerosis. With that in mind, it should become obvious that one of the first steps we have to take in the direction of curing these diseases is to identify the lipids that are involved and to determine what they specifically do.**

Many signaling lipids are generated by phospholipases such as phospholipase A<sub>2</sub>, which produces lysophospholipids and free fatty acids such as arachidonic acid. Further, many of the enzymes involved in the *de novo* pathways of lipid biosynthesis are also implicated in signaling. While our scientific interests include a comprehensive characterization of the roles played by both biosynthesis and remodeling pathways to overall cell signaling, our current research focuses primarily on the enzymes involved in maintaining the composition and levels of different fatty acids in biological membranes, i.e. phospholipases and acyltransferases. It is becoming clear that the phospholipid composition of biological membranes is very dynamic and that cells likely sustain many biological functions with different but somehow equivalent lipid compositions rather than a single one. Taking this concept a bit further, one could speculate that perhaps it is that, when the different lipid classes and subclasses interact to form a biological membrane, not all concentrations of each species are possible or permitted

(or required). Something like quantum lipid states? Fascinating indeed. In our laboratory we combine a range of chemical, biochemical, pharmacological, and molecular cell biology techniques to study lipid metabolism and signaling in physiology and pathophysiology. Within this context, our current goals can be summarized into five points, which are described below. This report covers the research activities of our lab from the beginning until December 2020.

## (1) Cellular regulation of phospholipase A<sub>2</sub>.

Phospholipase A<sub>2</sub> enzymes catalyze a key reaction in signaling, i.e. the release of arachidonic acid and other polyunsaturated fatty acids from the *sn*-2 position of cellular glycerophospholipids. The products of phospholipase A<sub>2</sub> action, free fatty acids and lysophospholipids may act as signaling molecules on their own, and also serve as a precursors for the synthesis of platelet-

activating factor or the eicosanoids. Our group has a long history in studying the mechanisms of regulation of phospholipase A<sub>2</sub> in resting and stimulated cells [reviews: 1–9]. Our work has highlighted the differential contribution of various phospholipase A<sub>2</sub>s to the formation of cellular lysophospholipid pools, and the important role that group VIA phospholipase A<sub>2</sub> plays in this process [10–12]. This latter enzyme appears to serve multiple roles in cells, and delineating some of these has been the subject of many studies. Specifically, we have studied the involvement of group VIA phospholipase A<sub>2</sub> in modulating lysozyme secretion as well as its various roles in cell proliferation and apoptosis [13–16]. We have identified a hitherto unrecognized preference of this enzyme for choline phospholipids containing palmitic acid at the *sn-1* position [17]. This preference is found in cells but not in cell-free assays, which suggests a key role for cell compartmentalization in the regulation of group VIA cytosolic phospholipase A<sub>2</sub> $\alpha$  activity under pathophysiological conditions. More recent work has shown that the enzyme is a major effector for the stimulated mobilization of two fatty acids that may possess anti-inflammatory activity, namely adrenic acid [18] and palmitoleic acid and its positional isomers [19].

Subcellular localization studies of various phospholipase A<sub>2</sub> forms have been conducted [20,21]. Various determinants and signaling events that regulate the subcellular localization of the arachidonate-specific cytosolic group IVA phospholipase A<sub>2</sub> $\alpha$  have been described in detail. Among these, we have unveiled the role of a cationic cluster present in the catalytic domain of the protein in regulating membrane binding via interaction with anionic phospholipids. The involvement of phosphorylation reactions in regulating binding of the enzyme to phagosomes has been characterized as well [22–25]. Further work has led to the identification of the cytosolic group IVA phospholipase A<sub>2</sub> as an early key factor for adipocyte differentiation *in vitro*, and *in vivo* during high fat diet-induced obesity [26].

Studies on the secreted group V phospholipase A<sub>2</sub> have shown that this enzyme is strongly upregulated in human macrophages by interleukin-4, but not by interferon- $\gamma$  plus lipopolysaccharide. We found that the increased expression of the enzyme in interleukin-4-treated macrophages serves to regulate the cellular levels of ethanolamine lysophospholipids that are necessary to support the elevated phagocytic response that these cells exhibit [27]. These results raise the provocative idea that group V phospholipase A<sub>2</sub> may act as a bi-faceted enzyme in innate immunity and inflammation, playing

either pro- or anti-inflammatory roles depending on conditions.

## (2) **Signaling mechanisms involved in the biosynthesis of eicosanoids by cells of the immune system.**

The eicosanoids are a large family of bioactive mediators that derive from the enzymatic oxygenation of arachidonic acid. The eicosanoids are biomedically important because they mediate all four signs of inflammation, namely heat, redness, swelling and pain. Controlling the formation of eicosanoids has been found to be of great benefit for the treatment of acute and chronic inflammatory diseases. Recently, we have characterized extensively the differences in arachidonate mobilization and eicosanoid metabolism by agonists acting via Toll-like receptors [28–30]. Overall, our results provide support to a model whereby secreted group V phospholipase A<sub>2</sub> may contribute to the eicosanoid biosynthetic response in some cases, by increasing activation of cytosolic group IVA phospholipase A<sub>2</sub> through amplification of phosphorylation cascades. This represents another instance of cross talk between secreted and cytosolic phospholipase A<sub>2</sub>s. This is a concept that has been around for a long time but still remains poorly characterized in molecular terms. Regarding the interaction of exogenous secreted phospholipase A<sub>2</sub> forms with cells, we have identified a mechanism connecting endogenous cytosolic phospholipase A<sub>2</sub> with the exogenous group V enzyme via the formation of hydroperoxyeicosatetraenoic acid. This metabolite is produced by cells in a cytosolic phospholipase A<sub>2</sub>-dependent manner, and appears to help the secreted enzyme to properly act on the membrane [31]. More recently, we have used a secreted group IIA phospholipase A<sub>2</sub>, isolated from snake venom to characterize in lipidomic terms its interaction with human cells [32,33]. Again much of the effects of group IIA phospholipase were found to involve the endogenous group IVA enzyme.

We have identified that lipin-1, a phosphatidate phosphatase enzyme residing on the surface of lipid droplets, may lie upstream group IVA phospholipase A<sub>2</sub> $\alpha$ , thus suggesting the existence of new and unexpected ways to regulate arachidonate mobilization and eicosanoid synthesis [34]. The lipin family of enzymes consists of 3 members, with one of them exhibiting 3 splicing variants. Aside from the aforementioned role for lipin-1, it is not known whether other lipin proteins regulate the eicosanoid cascade and we are conducting studies to explore this possibility. Importantly, these

enzymes appear to play significant roles not only in regulating phospholipid metabolism [14] but also in key aspects of innate immunity and inflammation [review: 35] such as lipopolysaccharide signaling and systemic inflammation [36,37], activation of the NLRP3 inflammasome [38], and inflammation-driven colon cancer development [39].

### **(3) Membrane fatty acid metabolism; incorporation into phospholipids and remodeling.**

The distribution of polyunsaturated fatty acids in cells is achieved by a finely regulated set of reactions of incorporation, remodeling and liberation of the fatty acids into, among and from phospholipids, respectively. These reactions ensure the proper distribution of the fatty acids within the various cellular phospholipid pools, which is important not only for membrane homeostasis but also for the execution of appropriate cell responses during physiological and pathophysiological activation. Our current work pays special attention to the interactions between omega-3 and omega-6 fatty acids, due to their importance as precursors of a large number of bioactive substances. Members of these two fatty acid families compete with each other for incorporation into the *sn*-2 position of membrane glycerophospholipids, which provides a control point for regulating their cellular levels, and hence the amount of oxygenated products generated after stimulation. Our work has led to the discovery of the selective involvement of lysophosphatidylcholine acyltransferase 3 (LPCAT3) as a novel signal-regulated enzyme involved in arachidonic acid metabolism in human monocytes [40]. Also, inhibition studies of phospholipid fatty acid incorporation and remodeling at various points have shown elevations of cellular free arachidonate levels that alter the balance of eicosanoids produced [17] and may also conduct to cell death by apoptosis [41]. Ongoing studies have aimed at characterizing at the cellular level the different specificities of the CoA-dependent routes of fatty acid incorporation (acyl-CoA synthetases and CoA-dependent acyltransferases), as well as the subsequent redistribution of the fatty acids into various cellular pools by CoA-independent transacylases [42,43]. Significant advances on these fronts have recently been made through the use of plasmalogen-deficient macrophage-like cells. Despite the well known fact that ethanolamine plasmalogens are enriched in arachidonic acid and other polyunsaturates, and that they constitute major substrates for coenzyme A-independent transacylation reactions, our recent work has indicated that cells deficient in plasmalogens remodel

arachidonate between phospholipids just as well as normal cells [44]. Thus it seems that overall phospholipid arachidonate remodeling is essentially independent of the amount of plasmalogen present in the cells. Compartmentalization of arachidonate in innate immune cells may rather depend on the relative distribution of the fatty acid between classes (ethanolamine versus choline versus inositol headgroups) rather than on specific molecular species within classes (i.e., alkenylacyl versus alkylacyl versus diacyl species) [44]. In addition, our results have implicated an ortholog of cytosolic group IVA phospholipase A<sub>2</sub>, namely the group IVC enzyme (cytosolic phospholipase A<sub>2</sub>γ) in phospholipid arachidonate remodeling [44]. The extent of cellular coenzyme A-independent transacylation activity that this enzyme accounts for is not known at present. Work is currently in progress to clarify this point, and also whether the enzyme is constitutively active or its activity increases after agonist stimulation.

While the finding that cellular plasmalogen status does not influence arachidonate remodeling was clearly unanticipated, our studies with plasmalogen-deficient cells have uncovered essential roles for ethanolamine plasmalogens in regulating other macrophage responses such as phagocytosis [45] and priming with bacterial lipopolysaccharide [46]. Regarding the former, it seems likely that ethanolamine plasmalogens contribute to a substantial part of the ethanolamine lysophospholipid pool that is necessary to maintain the phagocytic response of macrophages [27], as mentioned in preceding paragraphs. Regarding the latter, an interesting scenario emerges from our data, suggesting that lipopolysaccharide priming of macrophages slows down the coenzyme A-independent movement of arachidonate between phospholipids. This results in a reduced transfer of arachidonate from choline to ethanolamine phospholipids. Higher amounts of the fatty acid in choline phospholipids in the primed cells would mean that the phospholipase is able to mobilize greater amounts of the free fatty acid from this phospholipid class after a second stimulation, due to compartmentalization of the fatty acid [46]. This scenario nicely reconciles the observations that choline phospholipids are not the major arachidonate-containing phospholipid class in macrophages, yet they seem to constitute the major source of arachidonic acid that is mobilized during cellular activation.

In other series of experiments we have found that the extent to which arachidonate moves between phospholipids appears to depend on the nature of the triggering stimulus. Studies comparing the effects produced by

native zymosan (primarily actin through receptors for  $\beta$ -glucan) versus opsonized zymosan (primarily acting through Fc receptors), have indicated that the latter remodels arachidonate at a slower rate [47]. Following a similar rationale to that described in the preceding paragraph, this results in greater availability of the fatty acid in choline phospholipids, and hence in a stronger arachidonate release response [47]. Collectively, our research supports the general concept that differential stimulation of phagocytic cells promotes selective lipid turnover and, therefore, the appearance of specific lipid signatures for each activation condition.

#### **(4) Biosynthesis and degradation of lipid droplets during cellular activation.**

Lipid droplets are dynamic cytoplasmic structures which, among many things, may function as docking platforms for a number of enzymes involved in lipid signaling [8]. We have described the regulation of lipid droplet biosynthesis by various members of the phospholipase A<sub>2</sub> family of enzymes as well as the differential involvement of various lipid metabolic pathways in signal-regulated lipid droplet formation under proinflammatory conditions [48–51]. Our most significant results in this area of research suggest that phosphorylation activation of group IVA phospholipase A<sub>2</sub> $\alpha$  by multiple kinases drives lipid droplet formation in cells possibly by facilitating biogenesis of this organelle, not by regulating neutral lipid synthesis [51].

In defining the origin of the fatty acids accumulating in the neutral lipids of lipid droplets under a variety of stimulatory conditions (i.e. increased *de novo* fatty acid synthesis *versus* mobilization from membrane phospholipids) we made the unexpected finding that the lipid droplets of activated monocytes are enriched with an unusual fatty acid, *cis*-7-hexadecenoic acid (16:1n-9), a positional isomer of palmitoleic acid. The fatty acid shows significant anti-inflammatory activity *in vitro* and *in vivo* and might be regarded as a biomarker for early detection of cardiovascular disease [52]. Since *cis*-7-hexadecenoic acid accumulates in foamy monocytes in response to free arachidonic acid, a pro-inflammatory mediator, it is conceivable that metabolic changes underlying the formation and accumulation *cis*-7-hexadecenoic acid fatty acid into specific lipid classes are instrumental in showcasing effector functions of monocytes and macrophages toward the re-establishment of homeostasis during the course of inflammation processes.

Further work showed that phagocytic cells contain at least a third 16:1 positional isomer, namely *cis*-6-hexadecenoic acid (sapienic acid, 16:1n-10) This isomer also exhibits anti-inflammatory activity, although generally at higher concentrations than those observed for 16:1n-7 or 16:1n-9 [53]. All three 16:1 fatty acids are released upon stimulation of macrophages by calcium-independent group VIA phospholipase A<sub>2</sub> [19]. Interestingly, small parts of the released 16:1 fatty acids are utilized in phospholipid fatty acid remodeling reactions to enrich inositol lipids with 16:1, and also to form 16:1-containing fatty acid esters of hydroxy fatty acids (FAHFA) [19]. While the physiological and pathophysiological significance of the mobilization and metabolism of 16:1 fatty acids remains to be established in future work, our results have raised the challenging possibility that part of the anti-inflammatory activity of 16:1 fatty acids may be due to conversion to other lipid mediators. Work in this area is being actively pursued to improve our understanding of the biochemical pathways, cellular regulation, mechanisms of action, and spectrum of biological activity *in vivo* of 16:1 fatty acids.

We have described that human monocytes exposed to free arachidonic acid, a secretory product of endothelial cells, acquire a foamy phenotype which is due to the accumulation of cytoplasmic lipid droplets with high arachidonate content [51]. Using these cells we investigated whether the arachidonic acid present in neutral lipids is mobilized during activation conditions, and thus contributes to lipid mediator formation. Our results in this regard have suggested that this is not the case, and virtually all of the fatty acid that is released from activated cells comes from membrane phospholipids [54]. An intriguing possibility to consider is that arachidonate entry into neutral lipids may serve as an expandable storage pool to protect the cells from the toxicity of the fatty acid and/or to limit inflammation by reducing the amount of free fatty acid available for eicosanoid synthesis.

#### **(5) Lipidomics and metabolipidomics; identification and quantification of cellular lipidomes by mass spectrometry.**

The development of mass spectrometry techniques for the detection and analysis of lipids at a global scale provides us with a unique opportunity to characterize in detail the changes occurring in lipid metabolism as a consequence of cell activation [reviews: 6,7]. Since multiple lipid metabolic pathways are known to be activated by receptor

stimulation of cells, one of the major goals of our research in this area is to determine the origin and identity of the individual phospholipid molecular species that are produced under different conditions, as a first step to address their biological roles in cells. In the context of these studies, we have described a number of novel arachidonate-containing lipids, the levels of which increase during cell activation [55,56]. A remarkable finding from these studies was the discovery of the novel molecular species 1,2-diarachidonoyl-*sn*-glycero-3-phosphoinositol as a major but transient reservoir of arachidonic acid. The molecule appears to be produced by sequential remodeling of a preexisting phosphatidylinositol molecule first at position *sn*-2 and then at *sn*-1 with arachidonate, and could be involved in modulating innate immune responses such as superoxide anion production or secretion of antimicrobial hydrolases [57].

Other arachidonate-containing lipids have been identified in a stimulus- and cell type-dependent manner. A potentially interesting one is 1-palmitoleyl-2-arachidonoyl-*sn*-glycero-3-phosphoethanolamine, which is not present in resting monocytes but accumulates rapidly under receptor stimulation [56]. Again, these studies support the idea that changes in lipid content upon activation may be stimulus-specific, and also that cellular activation includes both common and stimulus-specific markers. Similar work has been conducted with lipids containing adrenic acid, the two-carbon elongation product of arachidonic acid [18,58]. Our data in this regard suggest that significant differences exist between the cellular mechanisms regulating the availability of adrenic acid and its immediate precursor arachidonic acid that could potentially be exploited to design strategies to control the production of oxygenated products of both fatty acids.

Lipidomic analyses of palmitoleic content in phagocytic cells have shown that this fatty acid and its isomers overwhelmingly accumulate in one single phospholipid species, namely 1-palmitoyl-2-palmitoleoyl-*sn*-glycero-3-phosphocholine [19,53]. This is striking, and raises the possibility that, similar to other choline phospholipid species, this palmitoleate-containing species may have biological activity on its own.

We have also initiated work to characterize the formation of FAHFA (fatty acid esters of hydroxy fatty acids) and the effect that cellular activation may have on certain species. Our work in this area has described the increased formation of a single palmitoleate-containing FAHFA species in activated macrophages [19]. The biological role of this species, if any, is unknown. Working with samples of human colon cancers we have found some connection between FAHFA levels and cell death, which led us to suggest that FAHFA formation in cancer cells could function as a buffer system that sequesters the hydroxy fatty acids into an inactive form, thereby avoiding apoptosis [59].

Finally, our expertise in lipidomics has made it possible for us to interact with other research groups, and these interactions have led to collaborative studies that focus on the identification of lipid alterations in various models of disease, including caveolin-1 deficiency [43,60–63], intestine epithelium permeability [64], hypertriglyceridemia [65], liver disorders [66–69], cancer [70], spinal cord injury [71], cold adaptation [72], and platelet activation and aggregation [73]. Several other lipidomic analyses are currently being carried out in our laboratory under various collaborative agreements.

## REFERENCES


1. Balsinde, J., M. V. Winstead, and E. A. Dennis. 2002. Phospholipase A<sub>2</sub> regulation of arachidonic acid mobilization. *FEBS Lett.* 531: 2–6.
2. Balsinde, J., and M.A. Balboa. 2005. Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A<sub>2</sub> in activated cells. *Cell. Signal.* 17: 1052–1062.
3. Balboa, M. A., and J. Balsinde. 2006. Oxidative stress and arachidonic acid mobilization. *Biochim. Biophys. Acta* 1761: 385–391.
4. Balsinde, J., R. Pérez, and M.A. Balboa. 2006. Calcium-independent phospholipase A<sub>2</sub> and apoptosis, *Biochim. Biophys. Acta* 1761: 1344–1350.
5. Pérez-Chacón, G., A. M. Astudillo, D. Balgoma, M. A. Balboa, and J. Balsinde. 2009. Control of free arachidonic acid levels by phospholipases A<sub>2</sub> and lysophospholipid acyltransferases. *Biochim. Biophys. Acta* 1791: 1103–1113.

6. Balgoma, D., O. Montero, M. A. Balboa, and J. Balsinde. 2010. Lipidomic approaches to the study of phospholipase A<sub>2</sub>-regulated phospholipid fatty acid incorporation and remodeling. *Biochimie* 92: 645–650.
7. Astudillo, A. M., D. Balgoma, M. A. Balboa, and J. Balsinde. 2012. Dynamics of arachidonic acid mobilization by inflammatory cells. *Biochim. Biophys. Acta* 1821: 249–256.
8. Guijas, C., J. P. Rodríguez, J. M. Rubio, M. A. Balboa, and J. Balsinde. 2014. Phospholipase A<sub>2</sub> regulation of lipid droplet formation. *Biochim. Biophys. Acta* 1841: 1661–1671.
9. Astudillo, A.M., M.A. Balboa, and J. Balsinde. 2019. Selectivity of phospholipid hydrolysis by phospholipase A<sub>2</sub> enzymes in activated cells leading to polyunsaturated fatty acid mobilization. *Biochim. Biophys. Acta* 1864: 772–783.
10. Balsinde, J. 2002. Roles of various phospholipases A<sub>2</sub> in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. *Biochem. J.* 364: 695–702.
11. Balboa, M. A., and J. Balsinde. 2002. Involvement of calcium-independent phospholipase A<sub>2</sub> in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. *J. Biol. Chem.* 277: 40384–40389.
12. Pérez, R., R. Melero, M.A. Balboa, and J. Balsinde. 2004. Role of group VIA calcium-independent phospholipase A<sub>2</sub> in arachidonic acid release, phospholipid fatty acid incorporation, and apoptosis in U937 cells responding to hydrogen peroxide. *J. Biol. Chem.* 279: 40385–40391.
13. Balboa, M. A., Y. Sáez, and J. Balsinde. 2003. Calcium-independent phospholipase A<sub>2</sub> is required for lysozyme secretion in U937 promonocytes. *J. Immunol.* 170: 5276–5280.
14. Fuentes, L., R. Pérez, M.L. Nieto, J. Balsinde, and M.A. Balboa. 2003. Bromoenol lactone promotes cell death by a mechanism involving phosphatidate phosphohydrolase-1 rather than calcium-independent phospholipase A<sub>2</sub>. *J. Biol. Chem.* 278: 44683–44690.
15. Pérez, R., M. A. Balboa, and J. Balsinde. 2006. Involvement of group VIA calcium-independent phospholipase A<sub>2</sub> in macrophage engulfment of hydrogen peroxide-treated U937 cells. *J. Immunol.* 176: 2555–2561.
16. Balboa, M. A., R. Pérez, and J. Balsinde. 2008. Calcium-independent phospholipase A<sub>2</sub> mediates proliferation of human promonocytic U937 cells. *FEBS J.* 275: 1915–1924.
17. Gil-de-Gómez, L., A. M. Astudillo, C. Guijas, V. Magrioti, G. Kokotos, M. A. Balboa, and J. Balsinde. 2014. Cytosolic group IVA and calcium-independent group VIA phospholipase A<sub>2</sub>s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages. *J. Immunol.* 192: 752–762.
18. Monge, P., A. Garrido, J.M. Rubio, V. Magrioti, G. Kokotos, M.A. Balboa, and J. Balsinde, J. 2020. The contribution of cytosolic group IVA and calcium-independent group VIA phospholipase A<sub>2</sub>s to adrenic acid mobilization in murine macrophages. *Biomolecules* 10: 542.
19. Astudillo, A.M., C. Meana, M.A. Bermúdez, A. Pérez-Encabo, M.A. Balboa, and J. Balsinde. 2020. Release of anti-inflammatory palmitoleic acid and its positional isomers by mouse peritoneal macrophages. *Biomedicines* 8: 480.
20. Balboa, M. A., Y. Shirai, G. Gaietta, M. H. Ellisman, J. Balsinde, and E. A. Dennis. 2003. Localization of group V phospholipase A<sub>2</sub> in caveolin-enriched granules in activated P388D<sub>1</sub> macrophage-like cells. *J. Biol. Chem.* 278: 48059–48065.
21. Shirai, Y., J. Balsinde, and E. A. Dennis. 2005. Localization and functional interrelationships among cytosolic group IV, secreted group V, and Ca<sup>2+</sup>-independent group VI phospholipase A<sub>2</sub>s in P388D<sub>1</sub> macrophages using GFP/RFP constructs. *Biochim. Biophys. Acta* 1735: 119–129.
22. Casas, J., M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, and M.A. Balboa. 2006. Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A<sub>2</sub> to perinuclear membranes and decreases its calcium requirement for translocation in live cells. *Mol. Biol. Cell* 17: 155–162.
23. Casas, J., M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, and M.A. Balboa. 2006. Overexpression of cytosolic group IVA phospholipase A<sub>2</sub> protects cells from calcium-dependent death. *J. Biol. Chem.* 281: 6106–6116.
24. Casas, J., C. Meana, E. Esquinas, M. Valdearcos, J. Pindado, J. Balsinde, and M. A. Balboa. 2009. Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A<sub>2</sub> to phagosomes in human macrophages. *J. Immunol.* 183: 2767–2774.
25. Casas, J., M. Valdearcos, J. Pindado, J. Balsinde, and M. A. Balboa. 2010. The cationic cluster of group IVA phospholipase A<sub>2</sub> (Lys488/Lys541/Lys543/Lys544) is involved in translocation of the enzyme to phagosomes in human macrophages. *J. Lipid Res.* 51: 388–399.
26. Peña, L., C. Meana, A. M. Astudillo, G. Lordén, M. Valdearcos, H. Sato, M. Murakami, J. Balsinde, and M. A. Balboa. 2016. Critical role for cytosolic group IVA phospholipase A<sub>2</sub> in early adipocyte differentiation and obesity. *Biochim. Biophys. Acta* 1861: 1083–1095.

27. Rubio, J. M., J. P. Rodríguez, L. Gil-de-Gómez, C. Guijas, M. A. Balboa, and J. Balsinde. 2015. Group V secreted phospholipase A<sub>2</sub> is up-regulated by interleukin-4 in human macrophages and mediates phagocytosis via hydrolysis of ethanolamine phospholipids. *J. Immunol.* 194: 3327–3339.
28. Pindado, J., J. Balsinde, and M. A. Balboa. 2007. TLR3-dependent induction of nitric oxide synthase in RAW 264.7 macrophage-like cells via a cytosolic phospholipase 2/cyclooxygenase-2 pathway. *J. Immunol.* 179: 4821–4828.
29. Ruipérez, V., J. Casas, M. A. Balboa, and J. Balsinde. 2007. Group V phospholipase A<sub>2</sub>-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages. *J. Immunol.* 179: 631–638.
30. Ruipérez, V., A. M. Astudillo, M. A. Balboa, and J. Balsinde. 2009. Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A<sub>2</sub>s. *J. Immunol.* 182: 3877–3883.
31. Balboa, M. A., R. Pérez, and J. Balsinde. 2003. Amplification mechanisms of inflammation: paracrine stimulation of arachidonic acid mobilization by secreted phospholipase A<sub>2</sub> is regulated by cytosolic phospholipase A<sub>2</sub>-derived hydroperoxyeicosatetraenoic acid. *J. Immunol.* 171: 989–994.
32. Leiguez, E., K. C. Giannotti, V. Moreira, M. H. Matsubara, J. M. Gutiérrez, B. Lomonte, J. P. Rodríguez, J. Balsinde, and C. Teixeira. 2014. Critical role of TLR2 and MyD88 for functional response of macrophages to a group IIA secreted phospholipase A<sub>2</sub> from snake venom. *PLoS One* 9: e93741.
33. Rodríguez, J.P., E. Leiguez, C. Guijas, B. Lomonte, J.M. Gutiérrez, C. Teixeira, M.A. Balboa, and J. Balsinde. 2020. A lipidomic perspective of the action of group IIA secreted phospholipase A<sub>2</sub> on human monocytes: lipid droplet biogenesis and activation of cytosolic phospholipase A<sub>2</sub> $\alpha$ . *Biomolecules* 10: 891.
34. Valdearcos, M., E. Esquinas, C. Meana, L. Gil-de-Gómez, C. Guijas, J. Balsinde, and M. A. Balboa. 2011. Subcellular localization and role of lipin-1 in human macrophages. *J. Immunol.* 186: 6004–6013.
35. Balboa, M.A., N. de Pablo, C. Meana, and J. Balsinde. 2019. The role of lipins in innate immunity and inflammation. *Biochim. Biophys. Acta* 1864: 1328–1337.
36. Valdearcos, M., E. Esquinas, C. Meana, L. Peña, L. Gil-de-Gómez, J. Balsinde., and M. A. Balboa. 2012. Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. *J. Biol. Chem.* 287: 10894–10904.
37. Meana, C., L. Peña, G. Lordén, E. Esquinas, C. Guijas, M. Valdearcos, J. Balsinde., and M. A. Balboa. 2014. Lipin-1 integrates lipid synthesis with proinflammatory responses during TLR activation in macrophages. *J. Immunol.* 193: 4614–4622.
38. Lordén, G., I. Sanjuán-García, N. de Pablo, C. Meana, I. Alvarez-Miguel, M. T. Pérez-García, P. Pelegrín, J. Balsinde, and M. A. Balboa. 2017. Lipin-2 regulates NLRP3 inflammasome by affecting P2X7 receptor activation. *J. Exp. Med.* 214: 511–528.
39. Meana, C., G.G. Rostán, L. Peña, L., G. Lordén, A. Cubero, A. Orduña, B. Györfy, J. Balsinde, and M.A. Balboa. 2018. The phosphatidic acid phosphatase lipin-1 facilitates inflammation-driven colon carcinogenesis. *JCI Insight* 3: e97506.
40. Pérez-Chacón, G., A. M. Astudillo, V. Ruipérez, M. A. Balboa, and J. Balsinde. 2010. Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes. *J. Immunol.* 184: 1071–1078.
41. Pérez, R., X. Matasch, A. Llebaria, M.A. Balboa, and J. Balsinde. 2006. Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. *J. Lipid Res.* 47: 484–491.
42. Astudillo, A. M., G. Pérez-Chacón, D. Balgoma, L. Gil-de-Gómez, V. Ruipérez, C. Guijas, M. A. Balboa, and J. Balsinde. 2011. Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells. *Biochim. Biophys. Acta* 1811: 97–103.
43. Astudillo, A. M., G. Pérez-Chacón, C. Meana, D. Balgoma, A. Pol, M. A. Del Pozo, M. A. Balboa, and J. Balsinde. 2011. Altered arachidonate distribution in macrophages from caveolin-1 null mice leading to reduced eicosanoid synthesis. *J. Biol. Chem.* 286: 35299–35307.
44. Lebrero, P., A.M. Astudillo, J.M. Rubio, L. Fernández-Caballero, G. Kokotos, M.A. Balboa, and J. Balsinde. 2019. Cellular plasmalogen content does not influence arachidonic acid levels or distribution in macrophages: a role for cytosolic phospholipase A<sub>2</sub> $\gamma$  in phospholipid remodeling. *Cells* 8: 799.
45. Rubio, J. M., A. M. Astudillo, J. Casas, M. A. Balboa, and J. Balsinde. 2018. Regulation of phagocytosis in macrophages by membrane ethanolamine plasmalogens. *Front. Immunol.* 9: 1723.
46. Gil-de-Gómez, L., A.M. Astudillo, P. Lebrero, M.A. Balboa, and J. Balsinde. 2017. Essential role for ethanolamine plasmalogen hydrolysis in bacterial lipopolysaccharide priming of macrophages for enhanced arachidonic acid release. *Front. Immunol.* 8: 1251.

47. Gil-de-Gómez, L., P. Monge, J.P. Rodríguez, A.M. Astudillo, M.A. Balboa, and J. Balsinde. 2020. Phospholipid arachidonic acid remodeling during phagocytosis in mouse peritoneal macrophages. *Biomedicines* 8: 274.
48. Gubern, A., J. Casas, M. Barceló, D. Barneda, X. de la Rosa, R. Masgrau, F. Picatoste, J. Balsinde, M. A. Balboa, and E. Claro. 2008. Group IVA phospholipase A<sub>2</sub> is necessary for the biogenesis of lipid droplets. *J. Biol. Chem.* 283: 27369–27382.
49. Gubern, A., M. Barceló, J. Casas, D. Barneda, R. Masgrau, F. Picatoste, J. Balsinde, M. A. Balboa, and E. Claro. 2009. Lipid droplet biogenesis induced by stress involves triacylglycerol synthesis that depends on group VIA phospholipase A<sub>2</sub>. *J. Biol. Chem.* 284: 5697–5708.
50. Gubern, A., M. Barceló, D. Barneda, J. M. López, R. Masgrau, F. Picatoste, C. E. Chalfant, J. Balsinde, M. A. Balboa, and E. Claro. 2009. JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A<sub>2</sub>. *J. Biol. Chem.* 284: 32359–32369.
51. Guijas, C., G. Pérez-Chacón, A. M. Astudillo, J. M. Rubio, L. Gil-de-Gómez, M. A. Balboa, and J. Balsinde. 2012. Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A<sub>2</sub>-dependent synthesis of lipid droplets in human monocytes. *J. Lipid Res.* 53: 2343–2354.
52. Guijas, C., C. Meana, A. M. Astudillo, M. A. Balboa, and J. Balsinde. 2016. Foamy monocytes are enriched in cis-7-hexadecenoic fatty acid (16:1n-9), a possible biomarker for early detection of cardiovascular disease. *Cell Chem. Biol.* 23: 689–699.
53. Astudillo, A.M., C. Meana, C. Guijas, L. Pereira, P. Lebrero, M.A. Balboa, and J. Balsinde. 2018. Occurrence and biological activity of palmitoleic acid isomers in phagocytic cells. *J. Lipid Res.* 59: 237–249.
54. Guijas, C., M.A. Bermúdez, C. Meana, A.M. Astudillo, L. Pereira, L. Fernández-Caballero, M.A. Balboa, and J. Balsinde. 2019. Neutral lipids are not a source of arachidonic acid for lipid mediator signaling in human foamy monocytes. *Cells* 8: 941.
55. Balgoma, D., O. Montero, M. A. Balboa, and J. Balsinde. 2008. Calcium-independent phospholipase A<sub>2</sub>-mediated formation of 1,2-diarachidonoylglycerophosphoinositol in monocytes. *FEBS J.* 275: 6180–6191.
56. Balgoma, D., A. M. Astudillo, G. Pérez-Chacón, O. Montero, M. A. Balboa, and J. Balsinde. 2010. Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. *J. Immunol.* 184: 3857–3865.
57. Gil-de-Gómez, L., A. M. Astudillo, C. Meana, J. M. Rubio, C. Guijas, M. A. Balboa, and J. Balsinde. 2013. A phosphatidylinositol species acutely generated by activated macrophages regulates innate immune responses. *J. Immunol.* 190: 5169–5177.
58. Guijas, C., A. M. Astudillo, L. Gil-de-Gómez, J. M. Rubio, M. A. Balboa, and J. Balsinde. 2012. Phospholipid sources for adrenic acid mobilization in RAW 264.7 macrophages: comparison with arachidonic acid. *Biochim. Biophys. Acta* 1821: 1386–1393.
59. Rodríguez, J. P., C. Guijas, A. M. Astudillo, J. M. Rubio, M. A. Balboa, and J. Balsinde. 2019. Sequestration of 9-hydroxystearic acid in FAHFA (fatty acid esters of hydroxy fatty acids) as a protective mechanism for colon carcinoma cells to avoid apoptotic cell death. *Cancers* 11: 524.
60. Cubells, L., S. Vila de Muga, F. Tebar, J. V. Bonventre, J. Balsinde, A. Pol, T. Grewal, and C. Enrich. 2008. Annexin A6-induced inhibition of cytosolic phospholipase A<sub>2</sub> is linked to caveolin-1 export from the Golgi. *J. Biol. Chem.* 283: 10174–10183.
61. Bosch, M., M. Marí, A. Herms, A. Fernández, A. Fajardo, A. Kassan, A. Giralt, A. Colell, D. Balgoma, E. Barbero, E. González-Moreno, N. Matías, F. Tebar, J. Balsinde, M. Camps, C. Enrich, S. P. Gross, C. García-Ruiz, E. Pérez-Navarro, J. C. Fernández-Checa, and A. Pol. 2011. Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility. *Curr. Biol.* 21: 681–686.
62. Sala-Vila, A., I. Navarro-Lérida, M. Sánchez-Alvarez, M. Bosch, C. Calvo, J. A. López, E. Calvo, C. Ferguson, M. Giacomello, A. Serafini, L. Scorrano, J. Enríquez, J. Balsinde, R. Parton, J. Vázquez, A. Pol, and M. A. del Pozo. 2016. Interplay between hepatic mitochondria-associated membranes, lipid metabolism and caveolin-1 in mice. *Sci. Rep.* 6: 27351.
63. Albacete, L.A., I. Navarro-Lérida, J.A. López, I. Martín-Padura, A.M. Astudillo, A. Ferrarini, M. Van-der-Heyden, J. Balsinde, G. Orend, J. Vázquez, and M.A. del Pozo. 2020. Extracellular matrix deposition is driven by caveolin1-dependent regulation of exosomal biogenesis and cargo sorting. *J. Cell Biol.* 219: e202006178.
64. Canali, M. M., L. Pedrotti, J. Balsinde, C. Ibarra, and S. G. Correa. 2012. Chitosan enhances transcellular permeability in human and rat intestine epithelium. *Eur. J. Pharm. Biopharm.* 80: 418–425.
65. Barroso, G., R. Rodríguez-Calvo, L. Serrano-Marco, A. M. Astudillo, J. Balsinde, X. Palomer, and M. Vázquez-Carrera. 2011. The PPAR $\beta/\delta$  activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1 $\alpha$ -lipin 1-PPAR $\alpha$  pathway leading to increased fatty acid oxidation. *Endocrinology* 152: 1848–1859.
66. Fernández, A., N. Matías, R. Fucho, V. Ribas, C. V. Montfort, N. Nuño, A. Baulies, L. Martínez, N. Tarrats, M. Mari, A. Colell, A. Morales, L. Dubuquoy, P. Mathurin, R. Bataller, J. Caballería, M. Elena, J. Balsinde, N. Kaplowitz, C. García-Ruiz, and

- J. C. Fernández-Checa. 2013. Acid sphingomyelinase is required for chronic alcohol-induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. *J. Hepatol.* 59: 805–813.
67. Fucho, R., L. Martínez, A. Baulies, N. Tarrats, A. Fernández, V. Ribas, A. M. Astudillo, J. Balsinde, P. García-Roves, M. Elena, I. Bergheim, S. Lotersztajn, C. Trautwein, H. Appelqvist, A. W. Paton, J. C. Paton, M. J. Czaja, N. Kaplowitz, J. C. Fernández-Checa, and C. García-Ruiz. 2014. Acid sphingomyelinase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage nonalcoholic steatohepatitis. *J. Hepatol.* 61: 1126–1134.
68. Castaño, C., E. Larequi, I. Belza, A. M. Astudillo, E. Martínez-Ansó, J. Balsinde, J. Argemi, T. Aragón, M. J. Moreno-Aliaga, J. Muntane, J. Prieto, and M. Bustos. 2014. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. *J. Hepatol.* 60: 1017–1025.
69. Pardo, V., A. González-Rodríguez, C. Guijas, J. Balsinde, and A. M. Valverde. 2015. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. *J. Biol. Chem.* 290: 11663–11677.
70. Herrero, A. B., A. M. Astudillo, M. A. Balboa, C. Cuevas, J. Balsinde, and S. Moreno. 2008. Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. *Cancer Res.* 68: 9779–9787.
71. Santos-Nogueira, E., C. López-Serrano, J. Hernández, N. Lago, A. M. Astudillo, J. Balsinde, G. Estivill-Torrús, F. R. de Fonseca, J. Chun, and R. López-Vales. 2015. Activation of lysophosphatidic acid receptor type 1 (LPA1) contributes to pathophysiology of spinal cord injury. *J. Neurosci.* 35: 10224–10235.
72. Vázquez, P., C. Hernández-Sánchez, C. Escalona-Garrido, L. Pereira, C. Contreras, M. López, J. Balsinde, F. de Pablo, and A.M. Valverde. 2018. Increased FGF21 in brown adipose tissue of tyrosine hydroxylase heterozygous mice: implications for cold adaptation. *J. Lipid Res.* 59: 2308–2320.
73. Gutiérrez-Herrero, S., C. Fernández-Infante, L. Hernández-Cano, S. Ortiz-Rivero, C. Guijas, V. Martín-Granado, J.R. González-Porras, J. Balsinde, A. Porras, and C. Guerrero. 2020. C3G contributes to platelet activation and aggregation by regulating major signaling pathways. *Signal Transduct. Target. Ther.* 5: 29.



**THE EICOSANOID  
RESEARCH DIVISION**  
VALLADOLID